Long-acting cabotegravir plus rilpivirine for treatment in adults with HIV-1 infection: 96-week results of the randomised, open-label, phase 3 FLAIR study
Published Online: 2021-04-?
Journal: The Lancet HIV•Publisher: Elsevier BV
Authors: Amy Cutrell•Ayesha Bassa•Chloe Orkin•Cynthia Brinson•Darrell H S Tan•David A Margolis•David Dorey•Denis Gusev•Enrique Bernal Morell•Herta Crauwels•Juan González García•Kati Vandermeulen•Kimberly Y Smith•Marty St Clair•Olaf Degen•Parul Patel•Patrick Philibert•Rodica Van Solingen-Ristea•Ronald D'Amico•Sandy Griffith•Shanker Thiagarajah•Shinichi Oka•Simon Vanveggel•Susan L Ford•Vasiliki Chounta•Veerle Van Eygen•William R Spreen
